Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $1.04 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same quarter last year, the company earned $0.88 EPS. The business’s quarterly revenue was up 25.0% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $135.99 on Monday. The company has a fifty day moving average of $136.63 and a two-hundred day moving average of $128.04. The company has a market capitalization of $13.53 billion, a PE ratio of 56.19 and a beta of 0.25. Neurocrine Biosciences has a 1 year low of $89.04 and a 1 year high of $148.37.

Insider Buying and Selling

In other news, CEO Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $140.69, for a total value of $380,847.83. Following the sale, the chief executive officer now directly owns 502,188 shares in the company, valued at $70,652,829.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the completion of the transaction, the chief executive officer now owns 502,188 shares of the company’s stock, valued at approximately $70,652,829.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David W. Boyer sold 456 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total transaction of $64,733.76. Following the sale, the insider now directly owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. Insiders sold 186,994 shares of company stock worth $25,806,409 in the last ninety days. Insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research report on Tuesday, April 23rd. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 24th. Mizuho increased their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. Finally, Oppenheimer reissued an “outperform” rating and issued a $200.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $142.38.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.